Shares of Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) saw an uptick in trading volume on Tuesday . 7,167 shares traded hands during mid-day trading, an increase of 377% from the previous session’s volume of 1,503 shares.The stock last traded at $9.58 and had previously closed at $9.5840.
Bavarian Nordic Stock Down 0.0%
The stock has a market capitalization of $2.28 billion, a PE ratio of 6.18 and a beta of 1.34. The stock’s 50 day moving average price is $10.17 and its 200-day moving average price is $10.80.
Bavarian Nordic Company Profile
Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.
The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.
Read More
- Five stocks we like better than Bavarian Nordic
- Why this rare resource setup is catching early attention
- Buy this Gold Stock Before May 15th, 2026
- My Epstein Story
- The Market Just Split in Two (URGENT)
- Central banks just did something they haven’t done since 1967
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
